HOOKIPA Phase 1 HB-200 data show unprecedented T cell response, favorable tolerability, and preliminary efficacy as monotherapy for advanced HPV16+ cancers

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing